Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
– Presentations include early data from Phase 1 study of NAM-NK in patients with non-Hodgkin lymphoma and multiple myeloma and data from NiCord® studies –
During the meeting, new data will be presented from the ongoing Phase 1 study of NAM-NK, an investigational, cell-based cancer immunotherapy, in patients with non-Hodgkin lymphoma and multiple myeloma. Additionally, there will be two presentations on NiCord®, an investigational universal bone marrow donor source, including an oral presentation describing translational data from the completed Phase 1/2 study of NiCord in patients with high-risk hematologic malignancies, or blood cancers. Initial data from a Phase 1/2 study of NiCord in patients with severe aplastic anemia will also be presented.
“We are pleased with our continued progress with NiCord, our late-stage
development program in bone marrow transplantation, and we are
encouraged by the clinical profile of NAM-NK that is emerging from this
first Phase 1 clinical study,” stated
Details about the presentations are as follows:
Time:
Title:
First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor
Natural Killer Cells for the Treatment of Relapsed/Refractory
Non-Hodgkin Lymphoma and Multiple Myeloma
Poster Number: 242
Lead
Author: Veronika Bachanova, M.D., Ph.D., associate professor of
medicine, division of hematology, oncology and transplantation,
Location:
Time:
Title:
Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Blood
Transplantation (UCB) for Refractory Severe Aplastic Anemia Results in
Rapid Engraftment and Expedites Immune Recovery
Poster Number: 295
Lead
Author:
Location:
Time:
Title: Rapid and Robust CD4+ and CD8+ T-, NK-,
B-Cell, Dendritic Cell, and Monocyte Reconstitution after
Nicotinamide-Expanded Cord Blood Transplantation
Abstract
Number: 69
Lead Author:
Location: Hilton
Americas Houston, Grand Ballroom G
Abstracts are available on the 2019TCT Meetings of ASBMT and CIBMTR website.
About NAM-NK
About NiCord
NiCord, the company’s lead clinical program, is
under development as a universal bone marrow transplant solution for
patients with high-risk hematologic malignancies. NiCord has been
granted Breakthrough Therapy designation by the
NAM-NK and NiCord are investigational therapies, and their safety and
efficacy have not been evaluated by the
About
Cautionary Note Regarding Forward Looking Statements
This
press release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995,
including with respect to the timing of the presentation of data related
to the Phase 1 study of NAM-NK, the Phase 1/2 study of NiCord for the
treatment of hematologic malignancies, and the Phase 1/2 study of NiCord
for the treatment of severe aplastic anemia, which statements are
subject to a number of risks, uncertainties and assumptions, including,
but not limited to the scope, progress and expansion of Gamida Cell’s
studies. In light of these risks and uncertainties, and other risks and
uncertainties that are described in the Risk Factors section of our
Registration Statement on Form F-1 filed with the
1ClinicalTrials.gov identifier NCT03019666.
2ClinicalTrials.gov
identifier NCT02730299.
3ClinicalTrials.gov identifier
NCT03173937.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190124005215/en/
Source:
Jaren Irene Madden
jaren@gamida-cell.com
1-617-286-6264
Krystle
Gibbs (media)
krystle@tenbridgecommunications.com
508-479-6358